Live Breaking News & Updates on Hong Kong Stock Exchange 1877 Hk

Stay updated with breaking news from Hong kong stock exchange 1877 hk. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Junshi Biosciences Announces NDA Acceptance in Hong Kong

SHANGHAI, China, April 24, 2024 (GLOBE NEWSWIRE) Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading. ....

United States , United Kingdom , San Francisco , Hong Kong Special Administrative Region , Hong Kong General , Hong Kong , South Africa , Zhi Li , Junshi Biosciences , American Society Of Clinical Oncology , National Reimbursement Drug List , Drug Office , Department Of Health , Ir Team , European Union , Australia Therapeutic Goods Administration , Singapore Health Sciences Authority , Journal Of The American Medical Association , Pr Team , Shanghai Junshi Biosciences Co Ltd , World Health Organization , European Medicines Agency , New Drug Application , Clinical Oncology , Nature Medicine , American Medical Association ,

Junshi Biosciences Announces 2023 Full Year Financial

SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading. ....

New Zealand , United Kingdom , South Africa , San Francisco , United States , Republic Of , Zhi Li , Junshi Bioscience , Junshi Biosciences , Therapeutic Goods Administration , National Medical Products Administration Of China , Ir Team , Shanghai Junshi Biosciences Co Ltd , Australian Government Department Of Health , Regulatory Agency , Pr Team , National Drug List For Basic Medical Insurance , Drug Administration , Deuremidevir Hydrobromide Tablets , National Medical Products Administration , Biologics License Application , Australian Government , Aged Care , New Chemical Entity , National Drug List , Basic Medical Insurance ,

Junshi Biosciences Announces Toripalimab's NDA Accepted by

SHANGHAI, China, Feb. 01, 2024 (GLOBE NEWSWIRE) Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading. ....

San Francisco , United States , United Kingdom , Zhi Li , Junshi Biosciences , Drug Administration , Oncology Center , Regulatory Agency , Journal Of The American Medical Association , European Union , World Health Organization , Pr Team , Shanghai Junshi Biosciences Co Ltd , Australia Therapeutic Goods Administration , American Society Of Clinical Oncology , Health Canada , Ir Team , Singapore Health Sciences Authority , National Reimbursement Drug List , European Medicines Agency , New Drug Application , Project Orbis , Clinical Oncology , Nature Medicine , American Medical Association , Southeast Asia ,

Junshi Biosciences Announces Lancet Infectious Diseases

SHANGHAI, China, Nov. 22, 2023 (GLOBE NEWSWIRE) Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading. ....

United States , Yun Ling , Zhi Li , Junshi Biosciences , Xinjiang Technical Institute Of Physics , Wuhan Institute Of Virology , Central Asian Center , Shanghai Junshi Biosciences Co Ltd , Shanghai Public Health Clinical Center , Global Research , Shanghai Institute Of Materia Medica , Development Chinese Academy Of Sciences China , Ir Team , Vigonvita Life Sciences Co Ltd , Pr Team , Lingang Laboratory , Chinese Academy Of Sciences , Lancet Infectious , State Key Laboratory , Infectious Diseases , Zhejiang University , Hospital Affiliated , New England Journal , Development President , Mindeudesivir Hydrobromide Tablets , Shanghai Institute ,

Junshi Biosciences Announces Acceptance of the Supplemental

SHANGHAI, China, July 19, 2023 (GLOBE NEWSWIRE) Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading. ....

United States , San Francisco , Ying Cheng , United Kingdom , Zhi Li , Junshi Biosciences , Junshi Bioscience , European Medicines Agency , Chinese Society Of Clinical Oncology , Regulatory Agency , Ir Team , Shanghai Junshi Biosciences Co Ltd , Drug Administration , Global Research , National Reimbursement Drug List , Pr Team , National Medical Products Administration , Professor Ying , Jilin Cancer Hospital , Chinese Society , Clinical Oncology , Jilin Cancer , Development President , Southeast Asia , Biologics License Application , Breakthrough Therapy ,